Full Press Release Details
- 2022 recipients include patient advocacy organizations from Brazil , Greece , Turkey , and the U.K. -
SOUTH PLAINFIELD, N.J. , Sept. 7, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy. The STRIVE program provides grants to non-profit patient advocacy organizations serving the Duchenne community. This year, grants will fund projects focused on formal learning, psychological support, sexuality, and skills-based training for people with Duchenne.
"We are proud to support the 2022 grant recipients for their work in the Duchenne community through our STRIVE Awards program. They have shown the broad range of needs in the Duchenne community, including programs supporting adults living with Duchenne," said Mary Frances Harmon , senior vice president, Corporate Relations, PTC Therapeutics. "The positive impact of the STRIVE grants will be across four countries this year, and we are privileged to provide the organizations with support to make their innovative projects a reality."
The categories for the 2022 STRIVE Awards are 'Innovative' for programs that help to address the unmet needs of the rare disease community, and 'Transition to Adulthood' for programs that support young people with Duchenne as they transition into independent adults. 'Transition to Adulthood' is a category introduced last year to celebrate the initiatives that support those living with Duchenne to lead independent, fulfilling, and rewarding lives. This year, PTC received 40 applications from organizations around the world.
The 2022 STRIVE Awards recipients are:
Innovative Category:
Transition to Adulthood Category:
About the STRIVE Awards Program PTC launched the St rategies to R ealize I nnovation, V ision, and E mpowerment (STRIVE) Awards program in 2015 to support initiatives that benefit the Duchenne community by increasing awareness, diagnosis, and education, and fostering the development of future patient advocates. Each year, an independent panel of external experts with knowledge in rare diseases, patient advocacy and funding initiatives, judge the entries for innovation, vision, and empowerment. Thirty-nine projects supporting the Duchenne community have received STRIVE grants since the program's inception.
For further information about the program and the 2022 award recipients, please visit the STRIVE Awards page on PTC's website at: www.ptcstriveawards.com .
About Duchenne Muscular Dystrophy Primarily affecting males, Duchenne muscular dystrophy is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk (loss of ambulation) as early as age ten, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and twenties.
More information regarding Duchenne is available at www.duchenneandyou.com .
For More Information:
Investors: Kylie O'Keefe +1 (908) 300-0691 [email protected]
Media: Jeanine Clemente +1 (908) 912-9406 [email protected]
Patient Organizations: Mary Frances Harmon +1 (908) 912-9205 or (866) 282-5873 [email protected]
SOURCE PTC Therapeutics, Inc.